These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38289714)

  • 1. Fragment-based screening targeting an open form of the SARS-CoV-2 main protease binding pocket.
    Huang CY; Metz A; Lange R; Artico N; Potot C; Hazemann J; Müller M; Dos Santos M; Chambovey A; Ritz D; Eris D; Meyer S; Bourquin G; Sharpe M; Mac Sweeney A
    Acta Crystallogr D Struct Biol; 2024 Feb; 80(Pt 2):123-136. PubMed ID: 38289714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease.
    Douangamath A; Fearon D; Gehrtz P; Krojer T; Lukacik P; Owen CD; Resnick E; Strain-Damerell C; Aimon A; Ábrányi-Balogh P; Brandão-Neto J; Carbery A; Davison G; Dias A; Downes TD; Dunnett L; Fairhead M; Firth JD; Jones SP; Keeley A; Keserü GM; Klein HF; Martin MP; Noble MEM; O'Brien P; Powell A; Reddi RN; Skyner R; Snee M; Waring MJ; Wild C; London N; von Delft F; Walsh MA
    Nat Commun; 2020 Oct; 11(1):5047. PubMed ID: 33028810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
    Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
    Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment-based in silico design of SARS-CoV-2 main protease inhibitors.
    Ahmad S; Usman Mirza M; Yean Kee L; Nazir M; Abdul Rahman N; Trant JF; Abdullah I
    Chem Biol Drug Des; 2021 Oct; 98(4):604-619. PubMed ID: 34148292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
    Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
    Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode.
    Lockbaum GJ; Henes M; Lee JM; Timm J; Nalivaika EA; Thompson PR; Kurt Yilmaz N; Schiffer CA
    Biochemistry; 2021 Oct; 60(39):2925-2931. PubMed ID: 34506130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease.
    Gahlawat A; Kumar N; Kumar R; Sandhu H; Singh IP; Singh S; Sjöstedt A; Garg P
    J Chem Inf Model; 2020 Dec; 60(12):5781-5793. PubMed ID: 32687345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
    Hajbabaie R; Harper MT; Rahman T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.
    Günther S; Reinke PYA; Fernández-García Y; Lieske J; Lane TJ; Ginn HM; Koua FHM; Ehrt C; Ewert W; Oberthuer D; Yefanov O; Meier S; Lorenzen K; Krichel B; Kopicki JD; Gelisio L; Brehm W; Dunkel I; Seychell B; Gieseler H; Norton-Baker B; Escudero-Pérez B; Domaracky M; Saouane S; Tolstikova A; White TA; Hänle A; Groessler M; Fleckenstein H; Trost F; Galchenkova M; Gevorkov Y; Li C; Awel S; Peck A; Barthelmess M; Schlünzen F; Lourdu Xavier P; Werner N; Andaleeb H; Ullah N; Falke S; Srinivasan V; França BA; Schwinzer M; Brognaro H; Rogers C; Melo D; Zaitseva-Kinneberg JI; Knoska J; Peña-Murillo GE; Mashhour AR; Hennicke V; Fischer P; Hakanpää J; Meyer J; Gribbon P; Ellinger B; Kuzikov M; Wolf M; Beccari AR; Bourenkov G; von Stetten D; Pompidor G; Bento I; Panneerselvam S; Karpics I; Schneider TR; Garcia-Alai MM; Niebling S; Günther C; Schmidt C; Schubert R; Han H; Boger J; Monteiro DCF; Zhang L; Sun X; Pletzer-Zelgert J; Wollenhaupt J; Feiler CG; Weiss MS; Schulz EC; Mehrabi P; Karničar K; Usenik A; Loboda J; Tidow H; Chari A; Hilgenfeld R; Uetrecht C; Cox R; Zaliani A; Beck T; Rarey M; Günther S; Turk D; Hinrichs W; Chapman HN; Pearson AR; Betzel C; Meents A
    Science; 2021 May; 372(6542):642-646. PubMed ID: 33811162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimerization Tendency of 3CLpros of Human Coronaviruses Based on the X-ray Crystal Structure of the Catalytic Domain of SARS-CoV-2 3CLpro.
    Jo S; Kim HY; Shin DH; Kim MS
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188.
    Lockbaum GJ; Reyes AC; Lee JM; Tilvawala R; Nalivaika EA; Ali A; Kurt Yilmaz N; Thompson PR; Schiffer CA
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33503819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking.
    Schuller M; Correy GJ; Gahbauer S; Fearon D; Wu T; Díaz RE; Young ID; Carvalho Martins L; Smith DH; Schulze-Gahmen U; Owens TW; Deshpande I; Merz GE; Thwin AC; Biel JT; Peters JK; Moritz M; Herrera N; Kratochvil HT; ; Aimon A; Bennett JM; Brandao Neto J; Cohen AE; Dias A; Douangamath A; Dunnett L; Fedorov O; Ferla MP; Fuchs MR; Gorrie-Stone TJ; Holton JM; Johnson MG; Krojer T; Meigs G; Powell AJ; Rack JGM; Rangel VL; Russi S; Skyner RE; Smith CA; Soares AS; Wierman JL; Zhu K; O'Brien P; Jura N; Ashworth A; Irwin JJ; Thompson MC; Gestwicki JE; von Delft F; Shoichet BK; Fraser JS; Ahel I
    Sci Adv; 2021 Apr; 7(16):. PubMed ID: 33853786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
    Zhu L; George S; Schmidt MF; Al-Gharabli SI; Rademann J; Hilgenfeld R
    Antiviral Res; 2011 Nov; 92(2):204-12. PubMed ID: 21854807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-chymotrypsin-like protease in SARS-CoV-2.
    Al Adem K; Ferreira JC; Villanueva AJ; Fadl S; El-Sadaany F; Masmoudi I; Gidiya Y; Gurudza T; Cardoso THS; Saksena NK; Rabeh WM
    Biosci Rep; 2024 Aug; 44(8):. PubMed ID: 39036877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMR Spectroscopy of the Main Protease of SARS-CoV-2 and Fragment-Based Screening Identify Three Protein Hotspots and an Antiviral Fragment.
    Cantrelle FX; Boll E; Brier L; Moschidi D; Belouzard S; Landry V; Leroux F; Dewitte F; Landrieu I; Dubuisson J; Deprez B; Charton J; Hanoulle X
    Angew Chem Int Ed Engl; 2021 Nov; 60(48):25428-25435. PubMed ID: 34570415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and Identification of Novel Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach.
    El Bakri Y; Anouar EH; Ahmad S; Nassar AA; Taha ML; Mague JT; El Ghayati L; Essassi EM
    Appl Biochem Biotechnol; 2021 Nov; 193(11):3602-3623. PubMed ID: 34324152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design.
    Rut W; Lv Z; Zmudzinski M; Patchett S; Nayak D; Snipas SJ; El Oualid F; Huang TT; Bekes M; Drag M; Olsen SK
    Sci Adv; 2020 Oct; 6(42):. PubMed ID: 33067239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 M
    Soulère L; Barbier T; Queneau Y
    Comput Biol Chem; 2021 Jun; 92():107463. PubMed ID: 33677227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
    Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C
    Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
    Khatua K; Alugubelli YR; Yang KS; Vulupala VR; Blankenship LR; Coleman D; Atla S; Chaki SP; Geng ZZ; Ma XR; Xiao J; Chen PH; Cho CD; Sharma S; Vatansever EC; Ma Y; Yu G; Neuman BW; Xu S; Liu WR
    Antiviral Res; 2024 May; 225():105874. PubMed ID: 38555023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.